- Wegovy "a game changer in the fight against obesity"
- There are supply constraints but the company is on the right track to address them, Lewis says
Timothy Lewis, portfolio manager of JPMorgan European Growth & Income (JEGI), explains why the trust invests in pharmaceutical giant Novo Nordisk (DN:NOVO.B):
Novo Nordisk has been a long-term holding in the portfolio and one we remain very positive about. It is relatively unique in the pharma sector in that it has been almost singularly focused on insulin and diabetes for more than 100 years and it has leveraged that strength in diabetes care into a leading position in the inter-related issue of obesity.